SEC Form 4 · accession 0001209191-17-037512
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John M. Leonard
Officer — EVP, R&D · Director
Period of report
Jun 1, 2017
Accepted (ET)
Jun 5, 2017 · 7:55 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 1, 2017 | A | 7,800 | $12.06 | A | 7,800 | I | By Trust |
| Common StockF1 | Jun 1, 2017 | A | 600 | $12.09 | A | 8,400 | I | By Trust |
| Common StockF2 | holding | — | — | — | 466,408 | D | ||
| Common StockF3 | holding | — | — | — | 58,415 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares acquired and held by the John Leonard Defined Benefit Pension Plan and Trust.
- F2Includes 403 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2016.
- F3Shares held by the John M. Leonard 2015 Irrevocable Trust.